المؤلفون: Niraj Neupane, Sawyer Bawek, Sayuri Gurusinghe, Elham Moases Ghaffary, Omid Mirmosayyeb, Sangharsha Thapa, Carla Falkson, Ruth O’Regan, Ajay Dhakal

المصدر: Cancers, Vol 16, Iss 3, p 619 (2024)

مصطلحات موضوعية: breast cancer, estrogen receptor-positive, endocrine therapies, resistance, selective estrogen receptor degraders, SERDs, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

Relation: https://www.mdpi.com/2072-6694/16/3/619; https://doaj.org/toc/2072-6694; https://doaj.org/article/7cdd0e46faf94e3ebdb51fd0043d144e

الاتاحة: https://doi.org/10.3390/cancers16030619
https://doaj.org/article/7cdd0e46faf94e3ebdb51fd0043d144e

المؤلفون: Downton T, Zhou F, Segara D, Jeselsohn R, Lim E

المصدر: Drug Design, Development and Therapy, Vol Volume 16, Pp 2933-2948 (2022)

مصطلحات موضوعية: selective estrogen receptor degraders, breast cancer, estrogen receptor, Therapeutics. Pharmacology, RM1-950

وصف الملف: electronic resource

Relation: https://www.dovepress.com/oral-selective-estrogen-receptor-degraders-serds-in-breast-cancer-adva-peer-reviewed-fulltext-article-DDDT; https://doaj.org/toc/1177-8881

URL الوصول: https://doaj.org/article/4bcfb0033e914132adcfe214030aa9b0

المؤلفون: M. A. Frolova, M. B. Stenina, М. А. Фролова, М. Б. Стенина

المصدر: Meditsinskiy sovet = Medical Council; № 11 (2023); 41-47 ; Медицинский Совет; № 11 (2023); 41-47 ; 2658-5790 ; 2079-701X

مصطلحات موضوعية: алпелисиб, fulvestrant, selective estrogen receptor degraders, ESR1 mutations, PIK3CA mutations, alpelisib, фулвестрант, селективные дегрейдеры рецепторов эстрогена, ESR1 мутации, PIK3CA мутации

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/7667/6801; Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. https://doi.org/10.1038/nature11412.; Osborne C.K., Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med. 2011;62:233–247. https://doi.org/10.1146/annurevmed-070909-182917.; Gottardis M.M., Jordan V.C. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 1988;48(18):5183–5187. Available at: https://pubmed.ncbi.nlm.nih.gov/3409244/.; Gottardis M.M., Wagner R.J., Borden E.C., Jordan V.C. Differential ability of antiestrogens to stimulate breast cancer cell (MCF-7) growth in Vivo and in Vitro. Cancer Res. 1989;49(17):4765–4769. Available at: https://pubmed.ncbi.nlm.nih.gov/2758410/.; Gottardis M.M., Jiang S.-Y., Jeng M.-H., Jordan V.С. Inhibition of tamoxifenstimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 1989;49(15):4090–4093. Available at: https://pubmed.ncbi.nlm.nih.gov/2743303/.; Gottardis M.M., Ricchio M.E., Satyaswaroop P.G., Jordan V.С. Effect of steroidal and nonsteroidal antiestrogens on the growth of a tamoxifen-stimulated human endometrial carcinoma (EnCa101) in athymic mice. Cancer Res. 1990;50(11): 3189–3192. Available at: https://pubmed.ncbi.nlm.nih.gov/2334915/.; Bowler J., Lilley T.J., Pittam J.D., Wakeling A.E. Novel steroidal pure antiestrogens. Steroids. 1989;54(1):71–99. https://doi.org/10.1016/0039-128x(89)90076-7.; Wakeling A.E., Dukes M., Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res. 1991;51(15):3867–3873. Available at: https://pubmed.ncbi.nlm.nih.gov/1855205/.; Dauvois S., White R., Parker M.G. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci. 1993;106(Pt 4):1377–1388. https://doi.org/10.1242/jcs.106.4.1377.; Osborne C.K., Wakeling A., Nicholson R.I. Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action. Br J Cancer. 2004;90(1 Suppl.):S2–S6. https://doi.org/10.1038/sj.bjc.6601629.; Howell A., Osborne C.K., Morris C., Wakeling A.E. ICI 182,780 (Faslodex): development of a novel, “pure” antiestrogen. Cancer. 2000;89(4):817–825. https://doi.org/10.1002/1097-0142(20000815)89:43.0.co;2-6.; Tzukerman M.T., Esty A., Santiso-Mere D., Danielian P., Parker M.G., Stein R.B. et al. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions. Mol Endocrinol. 1994;8(1):21–30. https://doi.org/10.1210/mend.8.1.8152428.; Nicholson R.I., Gee J.M., Manning D.L., Wakeling A.E., Montano M.M., Katzenellenbogen B.S. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen-sensitive and -resistant experimental and clinical breast cancer. Ann N Y Acad Sci. 1995;761:148–163. https://doi.org/10.1111/j.1749-6632.1995.tb31376.x.; Harrison M., Laight A., Clarke D., Giles P., Yates Y. Pharmacokinetics and metabolism of fulvestrant after oral, intravenous and intramuscular administration in healthy volunteers. EJC. 2003;1(5):S171. https://doi.org/10.1016/s1359-6349(03)90596-9.; Robertson J.F., Harrison M.P. Equivalent single-dose pharmacokinetics of two different dosing methods of prolonged-release fulvestrant (‘Faslodex’) in postmenopausal women with advanced breast cancer. Cancer Chemother Pharmacol. 2003;52(4):346–348. https://doi.org/10.1007/s00280-003-0643-7.; McCormack P., Sapunar F. Pharmacokinetic profile of the fulvestrant loading dose regimen in postmenopausal women with hormone receptor–positive advanced breast cancer. Clin Breast Cancer. 2008;8(4):347–351. https://doi.org/10.3816/CBC.2008.n.040.; Ohno S., Rai Y., Iwata H., Yamamoto N., Yoshida M., Iwase H. et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010;21(12):2342–2347. https://doi.org/10.1093/annonc/mdq249.; Howell A., Robertson J.F., Quaresma Albano J., Aschermannova A., Mauriac L., Kleeberg U.R. et al. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002;20(16):3396–3403. https://doi.org/10.1200/JCO.2002.10.057.; Osborne C.K., Pippen J., Jones S.E., Parker L.M., Ellis M., Come S. et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002;20(16):3386–3395. https://doi.org/10.1200/JCO.2002.10.058.; Howell A., Robertson J.F., Abram P., Lichinitser M.R., Elledge R., Bajetta E. et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004;22(9):1605–1613. https://doi.org/10.1200/JCO.2004.02.112.; Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R. et al. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptorpositive advanced breast cancer. J Clin Oncol. 2010;28(30):4594–4600. https://doi.org/10.1200/JCO.2010.28.8415.; Di Leo A., Jerusalem G., Petruzelka L., Torres R., Bondarenko I.N., Khasanov R. et al. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014;106(1):djt337. https://doi.org/10.1093/jnci/djt337.; Robertson J.F., Llombart-Cussac A., Rolski J., Feltl D., Dewar J., Macpherson E. et al. Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol. 2009;27(27):4530–4535. https://doi.org/10.1200/JCO.2008.21.1136.; Robertson J.F., Bondarenko I.M., Trishkina E., Dvorkin M., Panasci L., Manikhas A. et al. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016;388(10063):2997–3005. https://doi.org/10.1016/S0140-6736(16)32389-3.; Goetz M.P., Toi M., Campone M., Sohn J., Paluch-Shimon S., Huober J. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017;35(32):3638–3646. https://doi.org/10.1200/JCO.2017.75.6155.; Finn R.S., Martin M., Rugo H.S., Jones S., Im S.A., Gelmon K. et al. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016;375(20):1925–1936. https://doi.org/10.1056/NEJMoa1607303.; Hortobagyi G.N., Stemmer S.M., Burris H.A., Yap Y.S., Sonke G.S., PaluchShimon S. et al. Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med. 2016;375(18):1738–1748. https://doi.org/10.1056/NEJMoa1609709.; Sledge G.W. Jr, Toi M., Neven P., Sohn J., Inoue K., Pivot X. et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017;35(25):2875–2884. https://doi.org/10.1200/JCO.2017.73.7585.; Cristofanilli M., Turner N.C., Bondarenko I., Ro J., Im S.A., Masuda N. et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425–439. https://doi.org/10.1016/S1470-2045(15)00613-0.; Slamon D.J., Neven P., Chia S., Fasching P.A., De Laurentiis M., Im S.A. et al. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018;36(24):2465–2472. https://doi.org/10.1200/JCO.2018.78.9909.; Llombart-Cussac A., Pérez-García J.M., Bellet M., Dalenc F., Gil-Gil M., RuízBorrego M. et al. PARSIFAL Steering Committee and Trial Investigators. Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer: A Randomized Clinical Trial. JAMA Oncol. 2021;7(12):1791–1799. https://doi.org/10.1001/jamaoncol.2021.4301.; Johnston S.R., Kilburn L.S., Ellis P., Dodwell D., Cameron D., Hayward L. et al. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013;14(10):989–998. https://doi.org/10.1016/S1470-2045(13)70322-X.; Fribbens C., O’Leary B., Kilburn L., Hrebien S., Garcia-Murillas I., Beaney M. et al. Plasma ESR1 mutations and the treatment of estrogen receptorpositive advanced breast cancer. J Clin Oncol. 2016;34(25):2961–2968. https://doi.org/10.1200/JCO.2016.67.3061.; Giuliano M., Schettini F., Rognoni C., Milani M., Jerusalem G., Bachelot T. et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. Lancet Oncol. 2019;20(10):1360–1369. https://doi.org/10.1016/S1470-2045(19)30420-6.; Wilson F.R., Varu A., Mitra D., Cameron C., Iyer S. Systematic review and network meta-analysis comparing palbociclib with chemotherapy agents for the treatment of postmenopausal women with HR-positive and HER2-negative advanced/metastatic breast cancer. Breast Cancer Res Treat. 2017;166(1):167–177. https://doi.org/10.1007/s10549-017-4404-4.; André F., Ciruelos E., Rubovszky G., Campone M., Rugo H.S., Iwata H. et al. Alpelisib for PIK3CA-mutated, hormone receptor–positive advanced breast cancer. N Engl J Med. 2019;380(20):1929–1940. https://doi.org/10.1056/NEJMoa1813904.; Rugo H.S., Neven P., Saffie I., Park Y.H., De Laurentiis M., Lerebours F. et al. Alpelisib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2– advanced breast cancer (ABC) who received chemotherapy or endocrine therapy (ET) as immediate prior treatment: BYLieve Cohort C primary results and exploratory biomarker analyses. Cancer Res. 2022;82(4):PD13–05. https://doi.org/10.1158/1538-7445.SABCS21-PD13-05.; https://www.med-sovet.pro/jour/article/view/7667

الاتاحة: https://www.med-sovet.pro/jour/article/view/7667
https://doi.org/10.21518/ms2023-189

المؤلفون: Chung-Liang Li, Sin-Hua Moi, Huei-Shan Lin, Ming-Feng Hou, Fang-Ming Chen, Shen-Liang Shih, Jung-Yu Kan, Chieh-Ni Kao, Yi-Chia Wu, Li-Chun Kao, Ying-Hsuan Chen, Yi-Chen Lee, Chih-Po Chiang

المصدر: International Journal of Molecular Sciences; Volume 23; Issue 18; Pages: 10539

مصطلحات موضوعية: breast cancer, endocrine therapy resistance, cross-resistance, selective estrogen receptor modulators (SERMs), selective estrogen receptor degraders (SERDs), aromatase inhibitors (AIs), The Cancer Genome Atlas (TCGA)

جغرافية الموضوع: agris

وصف الملف: application/pdf

Relation: Molecular Oncology; https://dx.doi.org/10.3390/ijms231810539

الاتاحة: https://doi.org/10.3390/ijms231810539

المؤلفون: Samitha Andrahennadi, Amer Sami, Mita Manna, Mehrnoosh Pauls, Shahid Ahmed

المصدر: Current Oncology; Volume 28; Issue 3; Pages: 1803-1822

مصطلحات موضوعية: breast cancer, hormone receptor-positive breast cancer, estrogen receptor-positive-breast cancer, systemic therapy, targeted therapy, antiestrogen therapy, selective estrogen receptor modulator, selective estrogen receptor degraders, cyclin-dependent kinases 4 and 6 inhibitors, aromatase inhibitors

وصف الملف: application/pdf

Relation: https://dx.doi.org/10.3390/curroncol28030168

الاتاحة: https://doi.org/10.3390/curroncol28030168

المؤلفون: Ferro A., Generali D., Caffo O., Caldara A., De Lisi D., Dipasquale M., Lorenzi M., Monteverdi S., Fedele P., Ciribilli Y.

المساهمون: Ferro A, Generali D, Caffo O, Caldara A, De Lisi D, Dipasquale M, Lorenzi M, Monteverdi S, Fedele P, Ciribilli Y., Ferro, A., Generali, D., Caffo, O., Caldara, A., De Lisi, D., Dipasquale, M., Lorenzi, M., Monteverdi, S., Fedele, P., Ciribilli, Y.

مصطلحات موضوعية: Breast cancer, Endocrine therapy, Estrogen receptor, Selective estrogen receptor degraders (SERDs)

Relation: info:eu-repo/semantics/altIdentifier/pmid/37673696; info:eu-repo/semantics/altIdentifier/wos/WOS:001105219600001; volume:50; issue:3-5; firstpage:90; lastpage:101; numberofpages:12; journal:SEMINARS IN ONCOLOGY; https://hdl.handle.net/11572/437817

الاتاحة: https://hdl.handle.net/11572/437817
https://doi.org/10.1053/j.seminoncol.2023.08.002

المؤلفون: Keşküş, Ayşe Gökçe

المساهمون: Karakayalı, Özlen Konu

مصطلحات موضوعية: Selective estrogen receptor degraders, TP53 signaling, CHRNA5, Transcriptomics, synergy analysis, Selective estrogen receptor modulators, 14q31.32 miRNA cluster, Estrogen signaling, miRNA

وصف الملف: xix, 186 leaves : illustrations (color), charts (color), graphics, tables; 30 cm.; application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=od______3533::ded61361cb25f0226e871fef7580704e
https://hdl.handle.net/11693/76589

المؤلفون: Keşküş, Ayşe Gökçe

المساهمون: Karakayalı, Özlen Konu

مصطلحات موضوعية: CHRNA5, Estrogen signaling, Selective estrogen receptor degraders, Selective estrogen receptor modulators, TP53 signaling, miRNA, 14q31.32 miRNA cluster, Transcriptomics, synergy analysis

وصف الملف: xix, 186 leaves : illustrations (color), charts (color), graphics, tables; 30 cm.; application/pdf

Relation: http://hdl.handle.net/11693/76589; B132987

الاتاحة: http://hdl.handle.net/11693/76589

المؤلفون: Maysoun Shomali, Dotty Paquin, F Garner, C. Richard Lyttle, Gary Hattersley

المصدر: Anti-Cancer Drugs

مصطلحات موضوعية: Cancer Research, estrogen receptor inhibition, Estrogen receptor, Administration, Oral, blood–brain barrier, Rats, Sprague-Dawley, Bone Density, Medicine, Preclinical Reports, Pharmacology (medical), ortho-Aminobenzoates, Aromatase, biology, Brain Neoplasms, anticancer activity, tissue selectivity, Oncology, Selective estrogen receptor modulator, MCF-7 Cells, Heterografts, Female, medicine.drug, medicine.medical_specialty, medicine.drug_class, Ovariectomy, Mice, Nude, Antineoplastic Agents, Breast Neoplasms, Binding, Competitive, Breast cancer, breast cancer, Internal medicine, Animals, selective estrogen receptor degraders, Cell Proliferation, Pharmacology, Fulvestrant, business.industry, Phenylurea Compounds, Uterus, Estrogen Receptor alpha, Cancer, medicine.disease, Endocrinology, selective estrogen receptor modulators, Estrogen, biology.protein, Cancer research, Osteoporosis, business, Estrogen receptor alpha, Neoplasm Transplantation

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::447ae9daa046d4f3e640bb5362002063
http://europepmc.org/articles/PMC4560273

المؤلفون: Chandarlapaty, Sarat

المساهمون: SLOAN-KETTERING INST FOR CANCER RESEARCH NEW YORK

المصدر: DTIC

مصطلحات موضوعية: Medicine and Medical Research, BREAST CANCER, BIOCHEMISTRY, ESTROGENS, METASTASIS, MUTATIONS, PHARMACOLOGY, SERDS(SELECTIVE ESTROGEN RECEPTOR DEGRADERS)

وصف الملف: text/html

Relation: http://www.dtic.mil/docs/citations/ADA625621

الاتاحة: http://www.dtic.mil/docs/citations/ADA625621
http://oai.dtic.mil/oai/oai?&verb=getRecord&metadataPrefix=html&identifier=ADA625621

المؤلفون: Greene, Geoffrey L

المساهمون: CHICAGO UNIV IL

المصدر: DTIC

مصطلحات موضوعية: Biochemistry, Genetic Engineering and Molecular Biology, Anatomy and Physiology, Medicine and Medical Research, Pharmacology, BREAST CANCER, CHEMOTHERAPEUTIC AGENTS, ESTROGENS, GENES, RECEPTOR SITES(PHYSIOLOGY), INHIBITION, LIGANDS, METASTASIS, MUTATIONS, NEOPLASMS, RESISTANCE(BIOLOGY), TRANSCRIPTION(GENETICS), SERD(SELECTIVE ESTROGEN RECEPTOR DEGRADERS), LBD MUTATIONS, LBD(LIGAND BINDING DOMAIN), ESR1 GENE, ER(ESTROGEN RECEPTORS), ER MUTATIONS, BAZEDOXIFENE, ACQUIRED DRUG RESISTANCE, METASTATIC BREAST CANCER, SERM(SELECTIVE ESTROGEN RECEPTOR MODULATOR), TAMOXIFEN, FULVESTRANT, RALOXIFENE

وصف الملف: text/html

Relation: http://www.dtic.mil/docs/citations/ADA624026

الاتاحة: http://www.dtic.mil/docs/citations/ADA624026
http://oai.dtic.mil/oai/oai?&verb=getRecord&metadataPrefix=html&identifier=ADA624026

المؤلفون: Lu, Yunlong

المساهمون: Thatcher, Gregory, DiMagno, Steven, Johnson, Jeremy, Hickok, Jason, Moore, Terry, Bolton, Judy

مصطلحات موضوعية: Breast cancer, ER+, basic-amino selective estrogen receptor degraders (B-SERDs), Selective mixed-function estrogen receptor degraders (SMERDs)

وصف الملف: application/pdf

Relation: http://hdl.handle.net/10027/23690

الاتاحة: http://hdl.handle.net/10027/23690

المؤلفون: Yunlong Lu

مصطلحات موضوعية: Breast cancer, ER+, basic-amino selective estrogen receptor degraders (B-SERDs), Selective mixed-function estrogen receptor degraders (SMERDs)

Relation: http://hdl.handle.net/10027/23690; https://figshare.com/articles/thesis/Novel_Treatment_for_ER_Treatment_Resistant_Breast_Cancer/10856555

الاتاحة: http://hdl.handle.net/10027/23690
https://figshare.com/articles/thesis/Novel_Treatment_for_ER_Treatment_Resistant_Breast_Cancer/10856555